Product Information
PRAVASTATIN SODIUM 80 MG TAB is a generic product labeled by Quallent Pharmaceuticals Health LLC, priced at $0.1433 per EA under NDC 82009000805. Its NADAC has been published 237 times since Mar 23, 2022.
FDA first approved this application on Oct 23, 2006. Its Orange Book therapeutic-equivalence code is AB — FDA rates it therapeutically equivalent to (substitutable for) its reference product.
The High Outlier badge above means this manufacturer's average price in the PRAVASTATIN SODIUM market falls above Q3 + 1.5·IQR across all competing manufacturers. We only apply this flag in markets with four or more competitors. Full definition: glossary → outlier.
Strength
80 mg/1
Manufacturer
Quallent Pharmaceuticals Health LLCNDC
82009000805
Classification
Generic
Dosage Form
TABLET
Route
ORAL
Effective Date
9/23/2026
Active Ingredients
PRAVASTATIN SODIUMApproval Type
Generic (ANDA)
FDA Application
ANDA076341FDA Approved
10/23/2006
TE Code
AB
On Market Since
12/3/2021
Pharmacological Classes
Price Statistics
The NADAC for PRAVASTATIN SODIUM 80 MG TAB has been published 237 times since Mar 23, 2022, and over the history we have for it it has declined 4.4%. The table below summarizes its recorded NADAC range and movement.
| Current price | $0.1433 per EA |
|---|---|
| All-time high | $0.1890 (Jul 12, 2023) |
| All-time low | $0.1167 (Nov 20, 2024) |
| 52-week high | $0.1603 |
| 52-week low | $0.1433 |
| Median price | $0.1631 |
| Average price | $0.1615 |
| Largest weekly change | -31.4% (Nov 20, 2024) |
| Weeks tracked | 237 |
| Tracking since | Mar 23, 2022 |
Generic Alternatives
The matcher finds 4 manufacturers offering a NADAC-published product with this drug's active ingredient and strength in a comparable dosage form (cheapest from each manufacturer, up to 10 shown below). None of the shown alternatives sit below the current price. These are candidates to verify clinically, not guaranteed substitutes — see our generic drug prices guide.
Related Drugs
Same classification
Continue researching this drug
Use these direct paths to move from a single NDC into the surrounding market, manufacturer, class, and trend context.
Manufacturer
Quallent Pharmaceuticals Health LLC manufacturer profile
See the full portfolio, pricing trend, and other products from this labeler.
Drug market
PRAVASTATIN SODIUM market comparison
Compare this molecule across participating manufacturers and inspect the broader market price spread.
Therapeutic class
HMG-CoA Reductase Inhibitor class view
See how this drug behaves alongside other products in the same FDA pharmacologic class.
Trend hub
Latest market trends
Zoom back out to the weekly mover view and compare this NDC with the rest of the current NADAC release.
Guide
Understanding NADAC pricing
Use the explainer when you need context on how CMS publishes NADAC and how to interpret the number on this page.
Frequently asked questions
What is the NADAC price of PRAVASTATIN SODIUM 80 MG TAB?
The current National Average Drug Acquisition Cost (NADAC) for PRAVASTATIN SODIUM 80 MG TAB, manufactured by Quallent Pharmaceuticals Health LLC, is $0.1433 per EA (NDC 82009000805), effective Sep 30, 2026.
How has the price of PRAVASTATIN SODIUM 80 MG TAB changed over time?
Over the history we have for it, the NADAC for PRAVASTATIN SODIUM 80 MG TAB has declined 4.4%. It has been tracked across 237 weekly CMS publications since Mar 23, 2022.
What are the highest and lowest recorded NADAC prices for PRAVASTATIN SODIUM 80 MG TAB?
Since Mar 23, 2022, the NADAC for PRAVASTATIN SODIUM 80 MG TAB has ranged from a low of $0.1167 (Nov 20, 2024) to a high of $0.1890 (Jul 12, 2023), with a median of $0.1631 per EA.
Are there cheaper alternatives to PRAVASTATIN SODIUM 80 MG TAB?
4 manufacturers publish a NADAC-priced product with the same active ingredient and strength as PRAVASTATIN SODIUM 80 MG TAB in a comparable dosage form, but none are currently priced below it.
Who manufactures PRAVASTATIN SODIUM 80 MG TAB?
PRAVASTATIN SODIUM 80 MG TAB (NDC 82009000805) is labeled by Quallent Pharmaceuticals Health LLC, and CMS classifies it as a generic product.